Abstract
Antibody surveillance provides essential information for public health officials to work with communities to discuss the spread and impact of COVID-19 in communities. At the state of the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in the diagnostic testing was limited with many asymptomatic cases. Irrespective of symptom severity, antibodies develop within two to three weeks after disease onset and may persist 6 months or more, antibody surveillance is an important tool for tracking trends in past infections across diverse populations. This study includes adults and children recruited from a statewide sample of past 2014-2020 Survey of the Health of Wisconsin (SHOW) participants. SHOW, an ongoing population-based health examination study including a randomly selected sample of households, partnered with the Wisconsin Department of Health Services and the Wisconsin State Laboratory of Hygiene to conduct longitudinal antibody surveillance using the Abbott Architect SARS-CoV-2 IgG antibody test. WAVEs I and II of three planned WAVES were complete in mid-summer to late fall respectively, WAVE III is planned for early 2021. From WAVE I to WAVE II, crude estimates of seroprevalence in the total study population increased four to five-fold from 1.9% to 7.3%. Within the statewide probability sample, weighted estimates increased from an estimated 1.6% (95% CI:0.6-2.5%) seropositivity to 6.8% (95% CI:4.3-9.4%). Seroprevalence varied by health region in both waves, and significant disparities in smaller population groups were identified. Although there was no gender difference observed in WAVE I, seropositivity rates was higher in men 9.4% (95% CI:4.3, 14.3) compared to women 4.3% (2.7-5.3%) in WAVE II. This public health and academic partnership provides critical data for public health response to the pandemic and lays the foundation for future research into longer-term immunity, health impacts and population level disparities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding is provided by the Wisconsin Partnership Program and the Wisconsin Department of Health Services.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB exemption and approval for research were approved by the University of Wisconsin Health Sciences Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available from study investigators upon request.
